Article Instance

HTTP 200 OK
Allow: GET
Content-Type: application/json
Vary: Accept

{
    "pk": 1108,
    "title": "A Case Report of Prolonged Anaphylaxis after COVID-19 Vaccine",
    "subtitle": null,
    "abstract": "Introduction:\n As the medical community and world have combatted the coronavirus disease 2019 (COVID-19) pandemic, a significant advance was the development of a vaccine against the virus that has already claimed over 4.5 million lives worldwide. Vaccines manufactured by Pfizer-BioNTech and Moderna were the first two COVID-19 vaccines given emergency use authorization by the United States Food and Drug Administration. Preliminary data demonstrated not only the vaccines’ efficacy rates of greater than 95% after a second dose, but also marked safety. Initial data showed only 21 cases of anaphylaxis of greater than 1.8 million doses administered. The majority of those patients had a history of anaphylaxis and presented within the first 15 minutes after administration of the vaccine\nCase Report:\n We describe a patient who had an anaphylactic reaction to her second dose of the Pfizer BioNTech severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) vaccine with no prior history of allergic reactions or anaphylaxis. This reaction required multiple doses of epinephrine and a four-day hospitalization. We review both the available reports of anaphylaxis to the SAR CoV-2 vaccine and information on other prolonged cases of anaphylaxis.\nConclusion:\n Our case report is unique in that the patient, despite no prior history of anaphylaxis, had a prolonged course requiring a four-day hospitalization. To our knowledge this is one of the first case reports of prolonged anaphylaxis after the second dose of Pfizer BioNTech COVID-19 vaccine in a patient with no history of prior anaphylaxis.",
    "language": "en",
    "license": {
        "name": "Creative Commons Attribution 4.0",
        "short_name": "CC BY 4.0",
        "text": "Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.\r\n\r\nNo additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.",
        "url": "https://creativecommons.org/licenses/by/4.0"
    },
    "keywords": [
        {
            "word": "COVID-19 vaccine"
        },
        {
            "word": "anaphylaxis"
        },
        {
            "word": "prolonged"
        },
        {
            "word": "case report"
        }
    ],
    "section": "Case Reports",
    "is_remote": true,
    "remote_url": "https://escholarship.org/uc/item/9sg0v4t1",
    "frozenauthors": [
        {
            "first_name": "Lisa",
            "middle_name": "",
            "last_name": "Armstrong",
            "name_suffix": "",
            "institution": "RWJ Barnabas Health-Community Medical Center, Department of Emergency Medicine, Toms River, New Jersey",
            "department": "None"
        },
        {
            "first_name": "Nicole",
            "middle_name": "",
            "last_name": "Maguire",
            "name_suffix": "",
            "institution": "RWJ Barnabas Health-Community Medical Center, Department of Emergency Medicine, Toms River, New Jersey",
            "department": "None"
        }
    ],
    "date_submitted": "2021-12-14T18:54:51Z",
    "date_accepted": "2021-12-14T18:54:51Z",
    "date_published": "2021-12-14T18:59:22Z",
    "render_galley": null,
    "galleys": [
        {
            "label": "",
            "type": "",
            "path": "https://journalpub.escholarship.org/uciem_cpcem/article/1108/galley/849/download/"
        }
    ]
}